Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.

Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.

<h4>Objective</h4>To evaluate circulating visfatin and its relationship with disease activity and serum lipids in patients with early, treatment-naïve rheumatoid arthritis (RA).<h4>Methods</h4>Serum visfatin was measured in 40 patients with early RA before and after three mon...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ondřej Sglunda, Heřman Mann, Hana Hulejová, Markéta Kuklová, Ondřej Pecha, Lenka Pleštilová, Mária Filková, Karel Pavelka, Jiří Vencovský, Ladislav Senolt
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/0bd7bb5641ab4e61903bd3466fc3bf5c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0bd7bb5641ab4e61903bd3466fc3bf5c
record_format dspace
spelling oai:doaj.org-article:0bd7bb5641ab4e61903bd3466fc3bf5c2021-11-25T06:06:58ZDecreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.1932-620310.1371/journal.pone.0103495https://doaj.org/article/0bd7bb5641ab4e61903bd3466fc3bf5c2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25068448/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>To evaluate circulating visfatin and its relationship with disease activity and serum lipids in patients with early, treatment-naïve rheumatoid arthritis (RA).<h4>Methods</h4>Serum visfatin was measured in 40 patients with early RA before and after three months of treatment and in 30 age- and sex-matched healthy individuals. Disease activity was assessed using the Disease Activity Score for 28 joints (DAS28) at baseline and at three and 12 months. Multivariate linear regression analysis was performed to evaluate whether improved disease activity is related to serum visfatin or a change in visfatin level.<h4>Results</h4>Serum visfatin was significantly elevated in early RA patients compared to healthy controls (1.92±1.17 vs. 1.36±0.93 ng/ml; p = 0.034) and significantly decreased after three months of treatment (to 0.99±0.67 ng/ml; p<0.001). Circulating visfatin and a change in visfatin level correlated with disease activity and improved disease activity over time, respectively. A decrease in visfatin after three months predicted a DAS28 improvement after 12 months. In addition, decreased serum visfatin was not associated with an improved atherogenic index but was associated with an increase in total cholesterol level.<h4>Conclusion</h4>A short-term decrease in circulating visfatin may represent an independent predictor of long-term disease activity improvement in patients with early RA.Ondřej SglundaHeřman MannHana HulejováMarkéta KuklováOndřej PechaLenka PleštilováMária FilkováKarel PavelkaJiří VencovskýLadislav SenoltPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 7, p e103495 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Ondřej Sglunda
Heřman Mann
Hana Hulejová
Markéta Kuklová
Ondřej Pecha
Lenka Pleštilová
Mária Filková
Karel Pavelka
Jiří Vencovský
Ladislav Senolt
Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
description <h4>Objective</h4>To evaluate circulating visfatin and its relationship with disease activity and serum lipids in patients with early, treatment-naïve rheumatoid arthritis (RA).<h4>Methods</h4>Serum visfatin was measured in 40 patients with early RA before and after three months of treatment and in 30 age- and sex-matched healthy individuals. Disease activity was assessed using the Disease Activity Score for 28 joints (DAS28) at baseline and at three and 12 months. Multivariate linear regression analysis was performed to evaluate whether improved disease activity is related to serum visfatin or a change in visfatin level.<h4>Results</h4>Serum visfatin was significantly elevated in early RA patients compared to healthy controls (1.92±1.17 vs. 1.36±0.93 ng/ml; p = 0.034) and significantly decreased after three months of treatment (to 0.99±0.67 ng/ml; p<0.001). Circulating visfatin and a change in visfatin level correlated with disease activity and improved disease activity over time, respectively. A decrease in visfatin after three months predicted a DAS28 improvement after 12 months. In addition, decreased serum visfatin was not associated with an improved atherogenic index but was associated with an increase in total cholesterol level.<h4>Conclusion</h4>A short-term decrease in circulating visfatin may represent an independent predictor of long-term disease activity improvement in patients with early RA.
format article
author Ondřej Sglunda
Heřman Mann
Hana Hulejová
Markéta Kuklová
Ondřej Pecha
Lenka Pleštilová
Mária Filková
Karel Pavelka
Jiří Vencovský
Ladislav Senolt
author_facet Ondřej Sglunda
Heřman Mann
Hana Hulejová
Markéta Kuklová
Ondřej Pecha
Lenka Pleštilová
Mária Filková
Karel Pavelka
Jiří Vencovský
Ladislav Senolt
author_sort Ondřej Sglunda
title Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
title_short Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
title_full Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
title_fullStr Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
title_full_unstemmed Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
title_sort decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the perac cohort.
publisher Public Library of Science (PLoS)
publishDate 2014
url https://doaj.org/article/0bd7bb5641ab4e61903bd3466fc3bf5c
work_keys_str_mv AT ondrejsglunda decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT hermanmann decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT hanahulejova decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT marketakuklova decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT ondrejpecha decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT lenkaplestilova decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT mariafilkova decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT karelpavelka decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT jirivencovsky decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
AT ladislavsenolt decreasedcirculatingvisfatinisassociatedwithimproveddiseaseactivityinearlyrheumatoidarthritisdatafromtheperaccohort
_version_ 1718414146819588096

Ejemplares similares